Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P19525: Variant p.Ile506Val

Interferon-induced, double-stranded RNA-activated protein kinase
Gene: EIF2AK2
Feedback?
Variant information Variant position: help 506 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LB/B The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Isoleucine (I) to Valine (V) at position 506 (I506V, p.Ile506Val). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Similar physico-chemical property. Both residues are medium size and hydrophobic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 506 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 551 The length of the canonical sequence.
Location on the sequence: help DTAFETSKFFTDLRDGIISD I FDKKEKTLLQKLLSKKPEDR The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         DTAFETSKFFTDLRDGIIS-DIFDKK--EKTLLQKLLSKKPEDR

Mouse                         FTESEKIKFFESLRKGDFSNDIFDNK--EKSLLKKLLSEKP

Rat                           KTDSEKIEFFQLLRNGIFSDDIFDNK--EKSLLQKLLSSKP

Fission yeast                 QTNMERATKLQDLRRGNLPEEFVEQHICESSLILWMTAKDP

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 2 – 551 Interferon-induced, double-stranded RNA-activated protein kinase
Domain 267 – 538 Protein kinase
Region 266 – 551 Interaction with TRAF5
Mutagenesis 486 – 486 D -> V. 15-fold decrease in K3L binding affinity and thus resistance of mutated PKR to K3L inhibition.
Mutagenesis 489 – 489 F -> S. Loss of PKR inhibition by HCMV protein TRS1.
Mutagenesis 496 – 496 T -> K. No effect on PKR inhibition by HCMV protein TRS1.
Mutagenesis 502 – 502 I -> T. No effect on PKR inhibition by HCMV protein TRS1.
Mutagenesis 506 – 506 I -> V. No effect on PKR inhibition by HCMV protein TRS1.
Mutagenesis 510 – 510 K -> R. No effect on PKR inhibition by HCMV protein TRS1.
Mutagenesis 516 – 516 Q -> E. No effect on PKR inhibition by HCMV protein TRS1.
Beta strand 505 – 507



Literature citations
Patterns of somatic mutation in human cancer genomes.
Greenman C.; Stephens P.; Smith R.; Dalgliesh G.L.; Hunter C.; Bignell G.; Davies H.; Teague J.; Butler A.; Stevens C.; Edkins S.; O'Meara S.; Vastrik I.; Schmidt E.E.; Avis T.; Barthorpe S.; Bhamra G.; Buck G.; Choudhury B.; Clements J.; Cole J.; Dicks E.; Forbes S.; Gray K.; Halliday K.; Harrison R.; Hills K.; Hinton J.; Jenkinson A.; Jones D.; Menzies A.; Mironenko T.; Perry J.; Raine K.; Richardson D.; Shepherd R.; Small A.; Tofts C.; Varian J.; Webb T.; West S.; Widaa S.; Yates A.; Cahill D.P.; Louis D.N.; Goldstraw P.; Nicholson A.G.; Brasseur F.; Looijenga L.; Weber B.L.; Chiew Y.-E.; DeFazio A.; Greaves M.F.; Green A.R.; Campbell P.; Birney E.; Easton D.F.; Chenevix-Trench G.; Tan M.-H.; Khoo S.K.; Teh B.T.; Yuen S.T.; Leung S.Y.; Wooster R.; Futreal P.A.; Stratton M.R.;
Nature 446:153-158(2007)
Cited for: VARIANTS [LARGE SCALE ANALYSIS] GLU-428; VAL-439 AND VAL-506;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.